Simcere Pharmaceutical logo

2096 - Simcere Pharmaceutical Share Price

HK$8.1 -0.4  -4.1%

Last Trade - 26/02/21

Market Cap £2.01bn
Enterprise Value £2.36bn
Revenue £498.3m
Position in Universe 560th / 6135
Bullish
Bearish
Unlock 2096 Revenue
Momentum
Relative Strength (%)
1m -5.77%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -27.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 3,868 4,514 5,037 4,565 6,492 +14.1%
+113.8 +37.2 -47.4 +107
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, SimcerePharmaceutical Group Ltd revenues decreased 20% toRMB1.93B. Net income decreased 60% to RMB185.5M. Revenuesreflect a decrease in demand for the Company's products andservices due to unfavorable market conditions. Net incomealso reflects Research and development costs increase of80% to RMB454.1M (expense), Selling/General/Admin Expenseincrease of 24% to RMB193.5M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

2096 Revenue Unlock 2096 Revenue

Net Income

2096 Net Income Unlock 2096 Revenue

Normalised EPS

2096 Normalised EPS Unlock 2096 Revenue

PE Ratio Range

2096 PE Ratio Range Unlock 2096 Revenue

Dividend Yield Range

2096 Dividend Yield Range Unlock 2096 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
2096 EPS Forecasts Unlock 2096 Revenue
Profile Summary

Simcere Pharmaceutical Group Ltd is a company engaged in research and development, production and sales of drugs. The Company's main products are generic drugs, including Bicun used for central nervous system diseases, Jepaso and Jiebaili used for oncology, as well as Yingtaiqing used for autoimmune diseases. The Company also produces innovative drugs, such as Endostar used for oncology. The Company is also involved in providing promotion services for third-party drugs sold by medical institutions.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated November 30, 2015
Public Since October 27, 2020
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Index
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 2,608,641,618
Free Float (0.0%)
Eligible for
ISAs
SIPPs
2096 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 2096
Upcoming Events for 2096
Frequently Asked Questions for Simcere Pharmaceutical
What is the Simcere Pharmaceutical share price?

As of 26/02/21, shares in Simcere Pharmaceutical are trading at HK$8.1, giving the company a market capitalisation of £2.01bn. This share price information is delayed by 15 minutes.

How has the Simcere Pharmaceutical share price performed this year?

Shares in Simcere Pharmaceutical are currently trading at HK$8.1 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Simcere Pharmaceutical price has moved by % over the past year.

What are the analyst and broker recommendations for Simcere Pharmaceutical?

There are no analysts currently covering Simcere Pharmaceutical.

When will Simcere Pharmaceutical next release its financial results?

Simcere Pharmaceutical is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Simcere Pharmaceutical dividend yield?

Simcere Pharmaceutical does not currently pay a dividend.

Does Simcere Pharmaceutical pay a dividend?

Simcere Pharmaceutical does not currently pay a dividend.

When does Simcere Pharmaceutical next pay dividends?

Simcere Pharmaceutical does not currently pay a dividend.

How do I buy Simcere Pharmaceutical shares?

To buy shares in Simcere Pharmaceutical you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Simcere Pharmaceutical?

Shares in Simcere Pharmaceutical are currently trading at HK$8.1, giving the company a market capitalisation of £2.01bn.

Where are Simcere Pharmaceutical shares listed? Where are Simcere Pharmaceutical shares listed?

Here are the trading details for Simcere Pharmaceutical:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 2096
What kind of share is Simcere Pharmaceutical?

Based on an overall assessment of its quality, value and momentum, Simcere Pharmaceutical is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Simcere Pharmaceutical share price forecast 2021?

Shares in Simcere Pharmaceutical are currently priced at HK$8.1. At that level they are trading at 33.49% discount to the analyst consensus target price of 0.00.

Analysts covering Simcere Pharmaceutical currently have a consensus Earnings Per Share (EPS) forecast of 0.2258811493 for the next financial year.

How can I tell whether the Simcere Pharmaceutical share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Simcere Pharmaceutical. Over the past six months, the relative strength of its shares against the market has been %. At the current price of HK$8.1, shares in Simcere Pharmaceutical are trading at -3.61% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Simcere Pharmaceutical PE Ratio?

The Simcere Pharmaceutical PE ratio based on its reported earnings over the past 12 months is 22.95. The shares are currently trading at HK$8.1.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Simcere Pharmaceutical?

We were unable to find the directors for Simcere Pharmaceutical.

Who are the major shareholders of Simcere Pharmaceutical?

Here are the top five shareholders of Simcere Pharmaceutical based on the size of their shareholding:

Simcere Pharmaceutical Holding Ltd. Corporation
Percentage owned: 45.85% (1.20bn shares)
Artking Global Ltd. Corporation
Percentage owned: 23.26% (606.8m shares)
Fortune Fountain Investment Ltd. Corporation
Percentage owned: 4.64% (121.0m shares)
Premier Praise Ltd Corporation
Percentage owned: 4.41% (115.0m shares)
Ren (Jin Sheng) Individual Investor
Percentage owned: 4.3% (112.1m shares)
Similar to 2096
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.